Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Be 18 years of age or older~2. Subjects with American Cancer Society Clinical Stage 0 Ductal Carcinoma in Situ (DCIS) (Stage 0, Tis, N0, M0), IA (T1\*, N0, M0), IB ((T0, N1mi, M0) or T1\*, N1mi, M0)) or Stage IIA (T0, N1\*\*M0, or T1, N1\*\*, M0 or T2, N0, M0)1 breast cancer undergoing surgery to remove tumor draining LNs.~   Where:~  * Tis = Ductal carcinoma in situ~  * T0 = No evidence of primary tumor~  * T1 = Tumor ≤ 20 mm in greatest diameter~  * T1\* = Includes T1mi~  * T2 = Tumor \>20 mm but ≤ 50 mm in greatest diameter~  * N0 = No regional lymph node metastasisq1'~  * N1 = Metastasis to movable ipsilateral level I, II axillary LNs~  * N1\*\* = T0 and T1 tumors with nodal micro-metastasis only are excluded from Stage IIA and are classified Stage IB.~  * mi = Micro-metastasis~  * M0 = Disease has not metastasized from Stage IIA and are classified Stage IB.~  * M0= No evidence of metastasis~  * mi= Micrometastasis~3. Subjects with clinically negative nodal status (N0) with or without neoadjuvant chemotherapy~4. Subjects with negative metastatic involvement (M0)~5. Subjects of child-bearing potential must not be pregnant or lactating and must have a negative pregnancy test at Baseline~6. Have signed an approved informed consent form for the study~7. Be willing to comply with the protocol~Exclusion Criteria:~1. Have had prior axillary surgery or ipsilateral radiation in the breast(s) that is planned for the procedure~2. Advanced breast cancer subjects with stage IIB, III and IV~3. Known allergy or history of adverse reaction to ICG, iodine or iodine dyes~4. Subjects who have participated in another investigational study within 30 days prior to surgery~5. Pregnant or lactating subject~6. Subjects who, in the Investigator's opinion, have any medical condition that makes the subject a poor candidate for

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IC2000/SPY-PHI (Type: EXPERIMENTAL): Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.

Based on this trial design, predict the completion outcome and termination type (if applicable).